Post-earnings recap
Reported
Mon, May 11, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics faced challenges this quarter, particularly reflected in their EPS miss. The stock reacted with a slight decline of 1.04%, suggesting that investors were not overly surprised by the results. Management's cautious optimism may provide some reassurance, but the lack of revenue details leaves uncertainty about the company's immediate future.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | -10.00% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed cautious optimism about future opportunities despite the current challenges. They reiterated their focus on innovation.
Management noted ongoing challenges but emphasized commitment to long-term growth.
They highlighted the importance of innovation in their product pipeline.